ProCE Banner Activity

monarchE Subgroup Analysis by Age: Adjuvant Abemaciclib + ET in Older vs Younger Patients With High-Risk, Node-Positive HR+/HER2- EBC

Conference Coverage
Slideset

Adjuvant abemaciclib plus ET was associated with comparable efficacy in patients aged <65 vs ≥65 years but with more abemaciclib discontinuations in older patients.

Released: June 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.